Nan, Feifei; Fu, Xiaorui; Chen, Xinfeng; Li, Ling; Li, Xin; Wu, Jingjing; Feng, Xiaoyan; Wu, Xiaolong; Yan, Jiaqin; Zhang, Mingzhi published the artcile< Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience>, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate, the main research area is CD20 CAR T diffuse large B cell lymphoma immunotherapy; CAR-T cell therapy; PD-1 inhibitor; ibrutinib; resistance; venetoclax.
The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19- directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) Bcell malignancies. Although CAR-T cell therapy has promising effects, some patients are resistant to this treatment, leaving them with limited options. Therefore, strategies to overcome resistance to CAR-T cell therapy are needed. We retrospectively studied three R/R diffuse large B-cell lymphoma patients who were resistant to CAR-T cell therapy and whose disease was controlled after receiving pembrolizumab, 21D4 CAR-T cells, or ibrutinib and venetoclax. Some promising prevention and treatment strategies to overcome treatment resistance are also discussed.
Frontiers in Immunology published new progress about Acute myeloid leukemia. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics